Abstract
539P Biomarker analysis of IBI110 (anti-LAG-3 mAb) in combination with sintilimab (anti-PD-1 mAb) and chemotherapy as 1L treatment for advanced squamous non-small cell lung cancer (sqNSCLC)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have